A Safety and Pharmacokinetics Study of Niraparib plus androgen receptor-targeted therapy (apalutamide or abiraterone acetate and prednisone) in Men with Metastatic Castration-Resistant Prostate Cancer (protocol 64091742PCR1001)
The purpose of this study is to test the safety and tolerability of a combination of the study drugs niraparib and apalutamide in men with advanced prostate cancer. Niraparib is currently being studied for the treatment of ovarian, breast and advanced prostate cancer. Apalutamide is being studied for the treatment of advanced prostate cancer. This study tests different doses of the study drugs to see which dose combination is safer in people.
Prostate Cancer, Castration Resistant Prostate Cancer
1. Castration Resistant Prostate Cancer that is no longer responding to current therapy
2. Prior treatment with one of the following agents is required: Abiraterone acetate, enzalutamide, or apalutamide.
3. Prior treatment with at least 1 taxane-based chemotherapy (docetaxel and/or cabazitaxel) is required
4. A sample of tumor tissue is required, either previously collected or, if that is not available, you must be willing to have a biopsy to collect fresh tissue
5. Prior treatment with a PARP inhibitor is not allowed.
18 - NA
Healthy Volunteers Needed
Duration of Participation
Up to 24 months
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Janssen Research & Development, LLC